Evidence map›Paper›PMID 30029151›Full record

ArticleJournal of affective disorders2018

CHRNA7 copy number gains are enriched in adolescents with major depressive and anxiety disorders.

Madelyn A Gillentine, Ricardo Lozoya, Jiani Yin, Christopher M Grochowski, Janson J White, Christian P Schaaf, Chadi A Calarge

Abstract read
In one paragraph

Article in Journal of affective disorders, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. A novel anxiety-associated SNP identified inFrontiers in behavioral neuroscience · 2024
    Article
  7. Copy Number Variations in Neuropsychiatric Disorders.International journal of molecular sciences · 2023
    Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Madelyn A GillentineDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, United States; Jan and Dan Duncan Neurological Research Institute, Texas Children's Hospital, Houston, TX 77030, United States; Department of Genome Sciences, University of Washington, Seattle, WA, 98195, United States.
Ricardo LozoyaJan and Dan Duncan Neurological Research Institute, Texas Children's Hospital, Houston, TX 77030, United States.
Jiani YinDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, United States; Jan and Dan Duncan Neurological Research Institute, Texas Children's Hospital, Houston, TX 77030, United States.
Christopher M GrochowskiDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, United States.
Janson J WhiteDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, United States.
Christian P SchaafDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, United States; Jan and Dan Duncan Neurological Research Institute, Texas Children's Hospital, Houston, TX 77030, United States; Institute of Human Genetics, University Hospital Cologne, Cologne, Germany; Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany; Center for Rare Diseases, University Hospital Cologne, Cologne, Germany. Electronic address: schaaf@bcm.edu.
Chadi A CalargeMenninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX 77030, United States. Electronic address: chadi.calarge@bcm.edu.
Baylor College of Medicine · USNeurological Research Institute · USUniversity of Cologne · DE

Funding

UNIVERSITY OF IOWA CTSA FOR PEDIATRIC RESEARCHUL1RR024979 · NCRR · UNIVERSITY OF IOWA · PI ROSENTHAL, GARY E · 2007 to 2011
$31.8M
Steps towards a paternal gene activation therapy for Angelman syndromeU54HD083092 · NICHD · BAYLOR COLLEGE OF MEDICINE · PI NELSON, DAVID LOREN, SAMACO, RODNEY C · 2014 to 2019
$7.8M
PROGRAM IN HUMAN MOLECULAR GENETICST32GM008307 · NIGMS · BAYLOR COLLEGE OF MEDICINE · PI SHAULSKY, GAD · 1990 to 2020
$6.6M
Serotonin Reuptake Inhibitors and Bone Mineralization in AdolescentsR01MH090072 · NIMH · UNIVERSITY OF IOWA · PI CALARGE, CHADI A. · 2010 to 2014
$3.2M
Counteracting Risperidone-Induced Hyperprolactinemia in YouthsK23MH085005 · NIMH · UNIVERSITY OF IOWA · PI CALARGE, CHADI A. · 2009 to 2013
$866k
Long-Term Safety and Genetic Risk Factors of Risperdone Treatment in YouthR21MH080968 · NIMH · UNIVERSITY OF IOWA · PI CALARGE, CHADI A. · 2008 to 2010
$400k
Howard Hughes Medical Institute 52008107NCRR NIH HHS UL1 RR024979NICHD NIH HHS U54 HD083092NIGMS NIH HHS T32 GM008307NIMH NIH HHS K23 MH085005NIMH NIH HHS R01 MH090072NIMH NIH HHS R21 MH080968
6 · The paper itself

Abstract

objectiveNeuronal nicotinic acetylcholine receptors (nAChRs), specifically the α7 nAChR encoded by the gene CHRNA7, have been implicated in behavior regulation in animal models. In humans, copy number variants (CNVs) of CHRNA7 are found in a range of neuropsychiatric disorders, including mood and anxiety disorders. Here, we aimed to determine the prevalence of CHRNA7 CNVs among adolescents and young adults with major depressive disorder (MDD) and anxiety disorders.

methodsTwelve to 21 year-old participants with MDD and/or anxiety disorders (34% males, mean ± std age: 18.9 ± 1.8 years) were assessed for CHRNA7 copy number state using droplet digital PCR (ddPCR) and genomic quantitative PCR (qPCR). Demographic, anthropometric, and clinical data, including the Beck Anxiety Index (BAI), Beck Depression Inventory (BDI), and the Inventory of Depressive Symptoms (IDS) were collected and compared across individuals with and without a CHRNA7 CNV.

resultsOf 205 individuals, five (2.4%) were found to carry a CHRNA7 gain, significantly higher than the general population. No CHRNA7 deletions were identified. Clinically, the individuals carrying CHRNA7 duplications did not differ significantly from copy neutral individuals with MDD and/or anxiety disorders.

conclusionsCHRNA7 gains are relatively prevalent among young individuals with MDD and anxiety disorders (odds ratio = 4.032) without apparent distinguishing clinical features. Future studies should examine the therapeutic potential of α7 nAChR targeting drugs to ameliorate depressive and anxiety disorders.

Indexed as

Adolescentalpha7 Nicotinic Acetylcholine ReceptorAnxiety DisordersDNA Copy Number VariationsFemaleHumansMajor Depressive DisorderMaleReal-Time Polymerase Chain ReactionYoung Adultalpha7 Nicotinic Acetylcholine ReceptorChrna7 protein, human

Identifiers

PMID30029151
PMCPMC6273479
OpenAlexW2835275441

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.